METHODS We retrospectively reviewed patients with severe AS who underwent doppler carotid screening before surgical (SAVR) or transcatheter aortic valve replacement (TAVR) with a balloon-expandable valve between 1/2007 and 8/2014. Logistic regression models were used to determine the relation between 30-day post-procedure stroke and total (sum of left and right ICAS) and maximal unilateral ICAS. The model was adjusted for age, gender, history of atrial fibrillation, prior cerebrovascular disease and diabetes, left ventricular ejection fraction, and procedure type. 11 patients who underwent carotid intervention before valve replacement were excluded from the logistic models. Twosubgroup analyses were performed in patients that underwent TAVR and SAVR further adjusting for procedure specific details.
RESULTS 991 patients underwent ICAS screening prior to TAVR (n¼467) or SAVR (n¼529). In the entire group, the prevalence of !70% asymptomatic ICAS was 4.9% (n¼49) and incidence of 30-day stroke was 3.4% (n¼34). We did not find an association between stroke and either the total or maximal unilateral ICAS in our adjusted analysis for all patients (p¼0.09 and p¼0.31). There was no difference between those patients that underwent TAVR (p¼0.15 and 0¼0.44) or SAVR (p¼0.30 and p¼0.49, Figure 1 )
CONCLUSIONS The incidence of significant ICAS in preoperative screening for TAVR or SAVR is uncommon. Our study suggests that ICAS plays little or no role in the occurrence of procedure-related stroke after aortic valve replacement. Arguing against routine carotid Doppler screening before isolated TAVR or SAVR. BACKGROUND Moderate or severe aortic regurgitation (AR) in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) may adversely impact clinical outcomes. One of the modalities used to reduce residual AR is to implant a second device in the same procedure. This study details the results and outcome of patients who underwent a second CoreValve (CV) implantation to treat residual AR following the initial CV placement.
METHODS Patients with severe AS treated with CV device who had moderate or severe AR underwent optimized balloon sizing post dilation but continued to have significant residual AR post BAV and were subjected to a second CV implantation. AR post procedure was assessed by angiogram, echocardiography and hemodynamic indices. Clinical, imaging and procedural characteristics were recorded, and valvular function parameters were compared at baseline, post procedure, and at 30-days.
RESULTS
The study cohort included 161 patients with AS who were assigned to TAVR with CV. Of these 11 (7%) patients required a second device implantation at the same procedure due to residual moderate or severe AR. The mean annular diameter in these patients was 26.7 AE 2.6 mm. Valve size of the initial valve was 31mm in 8 patients (73%), 29mm in 2 (18%) and 26mm in 1 patient (9%). Average oversizing was 14 AE 9% and severe valve calcification on CT was present in 6 patients (55%). Procedural characteristics demonstrate a low or high initial implantation in 5 (45%) and 2 (18%) of the patients, respectively. Underexpansion of the initial device was noticed in 6 (54%). The second valve size matched the first valve size in all patients. Immediately post procedure reduction in AR was noted in all but one patient, with 4 (36%) patients reaching grade 2 AR and 6 (54%) patients achieving optimal level of grade 0-1 AR (Figure) . Second valve implantation was safe with no peri-procedural stroke or mortality. However, 6 (55%) patients developed acute kidney injury, 3 (27%) required pacemaker implantation and 4 (36%) developed new left bundle branch block.
CONCLUSIONS Second implantation of CV self-expanding valve for the treatment of significant residual AR is feasible and safe and associated with high immediate success rate, and should be considered as a modality for the treatment of residual moderate or severe AR after CV implantation.
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Post-Procedural And Follow-Up Management In Patients Undergoing Transcatheter Aortic Valve Implantation: Results From The Written (WoRldwIde TAVI ExpieNce) Survey BACKGROUND Transcatheter aortic valve implantation (TAVI) has been adopted worlwide, but there are still multiple areas where consensus and evidence are lacking. Post-procedural management according to the occurrence of conduction disturbances and antithrombotic treatment may vary across centers and valve types (balloon [BEV] and self-expandable [SEV] valve). The objectives of this study were to determine the real life practice related with post-TAVI management and antithrombotic treatment across different centers around the world.
METHODS From January to May 2015, an online survey was distributed worldwide in centers performing TAVI regardless the number of procedures and valve type. There was a responsible to distribute the survey in each country or region.
RESULTS A total of 167 centers (with 37843 TAVI procedures performed) responded the questionnaire from 27 different countries in Europe, North-America and South-America. Continuous ECG monitoring following TAVI was maintained during 24, 48 or !72 hours in 23%, 38% and 39% of the centers, respectively. Temporary pacemaker was removed at the end of the procedure in the absence of new conduction disturbances in 27% of patients (45% and 10% following BEV and SEV implantation, respectively). Transient A-V block occurring during valve implantation was usually not an indication for permanent pacemaker implantation for both valve types (>70%). New left bundle branch block was a frequent cause to extend temporary pacemaker indication (SEV 51%; BEV 41%), but not for permanent pacemaker implantation (<2% for both valves). Dual antiplatelet therapy was the most common antithrombotic treatment in patients without atrial fibrillation (89% of centers), with a variable duration (3 months in 44%, 6 months in 31%). In patients with atrial fibrillation, warfarin alone, warfarinþaspirin, warfarinþclopidogrel and triple therapy were given in 35%, 31%, 25% and 3% of the centers, respectively. Patients were followed in a TAVI clinic in only half (46%) of the centers.
CONCLUSIONS This survey highlights important variations in post-TAVI management according to ECG monitoring and temporary pacemaker across centers. Dual antiplatelet therapy is the most common antithrombotic treatment in the absence of other indication for anticoagulation, but antithrombotic treatment in patients with atrial fibrillation is highly variable. Future studies are needed to determine optimal post-TAVI management and follow-up.
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Left Bundle Branch Block and Need for Permanent Pacemaker Post TAVR
